Option chain shows key data for MediPharm Labs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for MediPharm Labs.

MediPharm Labs (OTC:MEDIF) Stock, Option Chain

MediPharm Labs

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

TWIC

Cannabis

Earnings

Government

Regulations

AAWH

AYRWF

CSE:MRMD

GRAM

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

IIPR

IMCC

INNO

INNPF

JSDA

LIEN

MEDIF

MRMD

ROMJF

SHF Holdings, Inc. - Class A Common Stock

SHFS

TLLTF

WEED

This week in cannabis: major mergers, innovative launches, key regulatory updates &amp; leadership changes drive industry transformation.

This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

pepi-stojanovski-MJSFNZ8BAXw-unsplash(1)

News

TSX:LABS

CBD-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday its third quarter financial results for the three months ended Sept. 30, 2024.&#34;Q3 2024 was a major step in the right direction towards profitability,&#34; Greg Hunter, the company&#39;s CFO, said. &#34;Paying off our debt and rationalizing facilities, pursuing cost efficiencies while growing our higher margin international revenues are all critical elements to position us for long-term sustainable growth.&#34;

CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth

elsa-olofsson-FkfIPqqv2Oc-unsplash(19)

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). &#34;We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability,&#34; David Pidduck, the company&#39;s CEO, said. &#34;The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats.&#34;

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

MEDIPHARM LABS CORP by Medipharm Labs Corporation

MediPharm Labs Corp

Medifast Inc

Small Cap

Press Releases

MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan

MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results

MediPharm Labs Reports Third Quarter Results

MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M

MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil

MediPharm Labs Provides Update on Previously Announced Sale of Napanee Facility to Kensana Health

MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health

MediPharm Labs to Sell its Hope Facility to Rubicon Organics for $4.5M

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results

MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results

TSXV:ROMJ

Comments

MediPharm Labs

MediPharm Labs (MEDIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga